Tissue Regenix Group reveals that trading in ordinary shares will remain suspended
Medical devices company Tissue Regenix has revealed that trading in its ordinary shares will remain suspended in light of uncertainty over its current trading position.
Earlier this month, Tissue Regenix announced that it has conditionally raised £17.5 million, before expenses, by way of the issue of Secured Convertible Loan Notes to Harwood Private Equity VI L.P, which is a substantial shareholder of the company.
In a statement issued on Monday, Tissue Regenix said: “Further to the announcement of 4 December 2025, the company expects to remain solvent assuming that the Resolutions are passed at the general meeting on 22 December 2025 and the initial £7.5m of the Secured Convertible Loan Note is drawn down shortly thereafter.
“However, in light of the ongoing financial challenges facing the company and continued uncertainty over its current trading position, the board does not believe it will be able to clarify Tissue Regenix's financial position with any degree of certainty ahead of the proposed cancellation date.
"As a result, trading in the ordinary shares will remain suspended ahead of cancellation on 7 January 2026. There will be a matched bargain facility in place from 7 January 2026 for a period of at least a year which will allow shareholders to trade on a matched bargain basis.”